In this trial, vorasidenib treatment resulted in low toxicity, prolonged progression-free survival (PFS), and delayed time to next intervention (TTNI) in patients with residual or recurrent IDH-mutant low-grade gliomas whose only prior treatment was surgery [47]. The gene discussed is IDH1; the disease is central nervous system cancer.